Abstract: Gemfibrozil, a peroxisome proliferator-activated receptor a (PPARa) agonist, is widely used for hypertriglyceridaemia and mixed hyperlipidaemia. Drug-drug interaction of gemfibrozil and other PPARa agonists has been reported. However, the role of PPARa in cytochrome P450 (CYP) induction by fibrates is not well known. In this study, wild-type mice were first fed gemfibrozil-containing diets (0.375%, 0.75% and 1.5%) for 14 days to establish a dose-response relationship for CYP induction. Then, wild-type mice and Ppara-null mice were treated with a 0.75% gemfibrozil-containing diet for 7 days. CYP3a, CYP2b and CYP2c were induced in a dose-dependent manner by gemfibrozil. In Ppara-null mice, their mRNA level, protein level and activity were induced more than those in wild-type mice. So, gemfibrozil induced CYP, and this action was inhibited by activated PPARa. These data suggested that the induction potential of CYPs was suppressed by activated PPARa, showing a potential role of this receptor in drug-drug interactions and metabolic diseases treated with fibrates.
Gemfibrozil belongs to a group of agents known as fibrate drugs which are prescribed primarily to treat hypertriglyceridaemia and mixed hyperlipidaemia associated with atherosclerosis [1] . Fibrate drugs promote the catabolism of triglyceride and very low-density lipoprotein and reduce the risk of cardiovascular events. Pharmacologically, they activate the peroxisome proliferator-activated receptor a (PPARa), alter adipokine release and modulate glucose homoeostasis [2, 3] . However, drug-drug interaction associated with gemfibrozil has raised many concerns in recent years.
Drug-drug interaction between gemfibrozil and statins was investigated to explore the mechanism of myotoxicity which led to the withdrawal of cerivastatin [4] . Gemfibrozil potently inhibits CYP2C9, and its metabolite gemfibrozil-1-O-glu is a mechanism-dependent inhibitor of CYP2C8 which is important for the oxidation of cerivastatin [5] . Additionally, CYP3A4, which mediates metabolism of cerivastatin, simvastatin and atorvastatin, could be inhibited by both gemfibrozil and gemfibrozil-1-O-glu [6] . Gemfibrozil also inhibits UDPglucuronyltransferases (UGTs) 1A1 and 1A3, which are responsible for the glucuronidation and elimination of statins [7] . Additionally, the uptake of cerivastatin by the hepatocyte transporter organic anion transporting polypeptide 1A4 was inhibited by both gemfibrozil and gemfibrozil-1-O-glu [6] . Based on the inhibitory actions, gemfibrozil was suggested as a CYP2C8 inhibitor by the U.S. Food and Drug Administration and the European Medicine Agency [8] .
Besides inhibition of xenobiotic metabolism, the inductive potential of gemfibrozil and other PPARa agonists for cytochrome P450 (CYPs) and UGTs has been evaluated. In HepG2 cells, PPARa agonist bezafibrate induces CYP2C8 mRNA and protein levels in a time-dependent manner [9] . In Sprague-Dawley rats, CYP3A1 and CYP3A2, and CYP2C6 activities were induced (32-77%) by gemfibrozil when the exposure concentration was in the clinical range [10] . In primary human hepatocytes, gemfibrozil induced CYP3A4 and CYP2C8 without pregnane X-receptor (PXR) activation [11] . In humanized mice, induction of CYP3A4 mRNA and protein by WY14,643 was verified [12] . However, little is known about PPARa's role for CYP induction potential by its agonists.
PPARa regulates genes involved in the metabolism of endogenous and exogenous substrates. PPARa also mediates the up-regulation of mRNA encoding CYP7A1 and CYP8B1 involved in bile acid synthesis and homoeostasis [13, 14] . In the dextran sulphate sodium-induced mouse colitis model, activation of PPARa-UGTs axis accelerated the elimination of intestinal bile acids, resulting in suppression of farnesoid X-receptor (FXR)-FGF15 signalling. The subsequent up-regulation of hepatic CYP7A1 increased de novo bile acid synthesis [15] . PPARa agonist perfluorodecanoic acid (PFDA), an environmental pollutant, was found to increase expression of Cyp2b10 (20 times), 3a11 (two times) and 4a14 (32 times) mRNAs in wild-type but not Ppara-null mice [16] . Both the disruptive action and protective action of PPARa in PFDA-induced hepatotoxicity were revealed recently [17] . These data indicated pleiotropic role of PPARa in liver metabolism and function. But a suppressive effect of activated PPARa on CYP induction potential has not been reported.
In this study, the dose-dependent induction of CYPs by the PPARa agonist gemfibrozil was investigated. Then Ppara-null mice fed a 0.75% gemfibrozil-containing diet were used to reveal a suppressive role of PPARa for induction potential of CYPs by gemfibrozil.
Materials and Methods
Chemicals and reagents. Gemfibrozil was obtained from Hunan Qianjin Xiangjiang Pharmaceutical Co. Ltd (Zhuzhou, China). TRIzol was obtained from Invitrogen (Carlsbad, USA). The reverse transcription kit was purchased from Thermo Fisher (Breinigsville, USA). The LightCycler 480 SYBR Green I Master Mix was purchased from Roche (Indianapolis, USA). Antibodies against CYP3A (sc-30621) and CYP2B1/2 (sc-73546) were products by Santa Cruz Biotechnologies (Delaware, USA). Antibodies against GAPDH (ab181602) and CYP2C (ab137015) were obtained from Abcam (Cambridge, UK). Midazolam, testosterone, pentoxyresorufin and diclofenac were purchased from Sigma-Aldrich (Sigma-Aldrich, St. Louis, MO, USA). 1 0 -Hydroxy-midazolam (1-OH-M), 6b-hydroxyl-testosterone (6b-OH-T), resorufin (Reso) and 4-hydroxydiclofenac (4-OH-D) were obtained from Toronto Research Chemical Inc. (Toronto, ON, Canada). Purified water was freshly prepared using a Millipore Elix (Bedford, MA, USA). All the other chemicals were of the highest grade from commercial sources.
Animals and treatment. The Ppara-null mice used in this study have been described previously [18] . Wild-type and Ppara-null mice are on the 129/Sv genetic background. The animal protocols were reviewed and approved by the Institutional Laboratory Animal Care and Use Committee of the Medical School at Ningbo University and the National Cancer Institute Animal Care and Use Committee. Wild-type and Ppara-null mice were maintained under a standard 12-hr light/dark cycle with free access to water and a commercial diet. Male, 5-to 7-week-old mice were acclimated to a commercial purified diet for 7 days before the experiment. Three groups of wildtype mice (n = 5 in each group) were fed with 0.375%, 0.75% and 1.5% gemfibrozil diet (g/g), respectively, for 14 days. This dosage was designed based on published data with close relevance to clinical regimen [13] . Considering the dose-response relationship observed in the wild-type mice, a new set of wild-type and Pparanull mice with the same background as the above were fed a 0.75% gemfibrozil-containing diet only for 7 days. The control groups for both mouse lines were treated with purified diet only. At the end of each experiment, all mice were weighed and killed by a CO 2 overdose, and blood was collected for analysis. Liver tissues harvested were flash-frozen in liquid nitrogen and stored at À80°C until analysis.
Quantitative polymerase chain reaction (Q-PCR) analysis. Total RNA from mouse hepatic tissues homogenized in TRIzol reagent was determined by Multiskan Go (Thermo Fisher Scientific, Waltham, USA). The reverse transcription system (20 lL) included the following items: 59 reaction buffer 4 lL, total mRNA 1 lg, Oligo dT18 1 lL, random primer 1 lL, 10 mM dNTPs Mix 2 lL, 200 U RevertAid M-MuLV RT 1 lL and 20 U RiboLock RNase Inhibitor 1 lL (Thermo Fisher Scientific, Waltham, USA). The synthesized cDNA was stored at À20°C and subjected to analysis within 7 days. The primer sequences, listed in table 1, were extracted from http://mouseprimerdepot.nci.nih.gov/. Each 10 lL of reaction contained total cDNA 1 lL, LightCycler 480 SYBR Green I Master Mix (FastStart Taq DNA Polymerase, reaction buffer, dNTPmix, SYBR Green I dye and MgCl 2 ) 5 lL (Indianapolis, IN, USA), forward primer 0.2 lL, reverse primer 0.2 lL, nuclease-free water 3.6 lL. Amplification was performed using 40 reaction cycles of 95°C 10 sec., 60°C 10 sec. and then 72°C 15 sec. The fluorescence signal was detected at the end of each cycle. All mRNA expression levels were normalized by transcription of internal standard 18S rRNA and expressed as a ratio compared with that of the control group which was arbitrarily set as 1 in each experiment. The classical function 2
ÀMMCt was used throughout all the qPCR data analysis.
Western blot analysis. Liver tissues were homogenized with a MagNA Lyser (Roche) using RIPA buffer (1:10, g/v) containing 1% PMSF (Thermo Fisher Scientific, Shanghai, China). Tissue debris was removed by centrifugation at 10,000 9 g and 4°C for 5 min. Total protein was quantified using a BCA protein assay kit from Beyotime Biotech Co., Ltd (Beyotime, Nantong, China). An equivalent volume of 59 SDS-PAGE sample loading buffer (Thermo Fisher Scientific, Shanghai, China) was added to the tubes that were boiled for 5 min. The samples were loaded and separated on 10% SDS-polyacrylamide electrophoresis gels. The samples were transblotted onto PVDF membranes blocked with 5% fat-free milk at 37°C for 2 hr. Membranes were incubated overnight with primary antibodies against CYP3A, CYP2B, CYP2C and GAPDH. After a second antibody incubation for 2 hr, the blotted membranes were exposed to ECL substrates (Advansta, Menlo Park, CA, USA), and the signals were detected by Tanon 4200SF (Tanon, Shanghai, China).
Assessment of induced CYP activities. Liver homogenate from 300 mg liver tissues was prepared in PB (0.1 M, 1 mM EDTA, 0.9% NaCl, pH 7.4) and centrifuged at 9000 9 g for 30 min. at 4°C. The supernatant was spun at 100,000 9 g for 60 min. at 4°C and then discarded. The microsomal preparations were resuspended in ice-cold PB (0.1 M, 1 mM EDTA, 0.25 M D-(+)-sucrose, pH 7.4). Protein concentration was determined using a BCA protein assay kit. Midazolam 1 0 -hydroxylation and testosterone 6b-hydroxylation were used as the marker reactions of CYP3A. Diclofenac 4-hydroxylation and pentoxyresorufin O-deethylation were used as marker reactions for CYP2C and CYP2B activity, respectively. To determine the maximal activity, the substrate concentrations were 4 K m based on human microsome data reported earlier [19] . The incubation was performed similarly as previously reported [10] . The reactions were terminated by the addition of 200 mL ice-cold acetonitrile with 0.04 mg/mL bezafibrate as the internal standard. The ion transitions m/z 342.1/ 324.6 for 1 0 -hydroxy-midazolam, m/z 305.3/269.2 for 6b-OH-T, m/z 312.1/265.8 for 4-hydroxy-diclofenac and m/z 213.9/186.0 for resorufin were determined using an ABI 3000 triple quadrupole mass spectrometer (Applied Biosystems, Foster City, CA, USA) coupled with HPLC (SHIMADZU 10A, Kyoto, Japan) and an MPS3C autosampler (GERSTEL, M€ ulheim an der Ruhr, Germany) controlled by Analyst 1.4.2 workstation software (Applied Biosystems). Relative abundance of the produced metabolites compared with internal standard was used to evaluate the CYP activities.
Statistical analysis. All the experimental values were expressed as mean AE S.D. Statistical analysis was performed using SPSS 13.0 (Chicago, IL, USA). One-way ANOVA, followed by Dunnett's post hoc tests, was used for multiple comparisons of data from wild-type mice dosed with three different gemfibrozil diets. The results following treatment in both wild-type and Ppara-null mice were analysed using a two-tailed, independent-sample t-test. The difference was considered significant when the p values were <0.05.
Results

Dose-response of CYP induction by gemfibrozil.
Messenger RNA, protein expression and metabolic activity were assayed to evaluate the dose-response relationship of the CYP induction by gemfibrozil. Cyp3a11 mRNA level was elevated 4.7, 5.9 and eight times after 0.375%, 0.75% and 1.5% gemfibrozil, respectively, compared with control mice, showing Cyp3a11 mRNA induction was dose dependent on gemfibrozil. A similar tendency was also observed for Cyp2c39 where the mRNA increased by 2.6, 4.4 and 8.5 times, respectively, after increasing doses of gemfibrozil. However, induction of Cyp2b10, Cyp2c29 and Cy2c37 was only observed in the 1.5% gemfibrozil group (4.5, 2.4, 2.5 times, respectively) ( fig. 1 ).
In accordance with the mRNA expression level of Cyp3a, Cyp2b and Cyp2c, Western blot results showed that levels of CYP3A, CYP2B and CYP2C were higher in gemfibrozil-treated than in control mice, and the tendency was also dose dependent ( fig. 2A) . CYP3A, CYP2B and CYP2C were moderately induced in the 0.375% gemfibrozil group and strongly induced in the 1.5% gemfibrozil group (fig. 2B) .
The activities of CYP3A, CYP2B and CYP2C were evaluated using an internal standard method. Similar to the mRNAs and proteins, CYP3A activity, according to 1-OH-M, increased by 3.4, 3.9, 7.4 times, respectively, in the 0.375%, 0.75% and 1.5% gemfibrozil groups and showed dose dependency ( fig. 3) . A much smaller dose-dependent increase in 6b-OH-T production as a result of CYP3A activity was also noted. Catalytic activity of CYP2B was only induced in the 1.5% gemfibrozil group by 2.3 times according to the resorufin metabolism. The activity of CYP2C showed a slight induction in the 0.375% gemfibrozil mice (1.4 times) and moderately in the 1.5% gemfibrozil group (two times) according to the production of 4-OH-D. However, the difference compared with that of the control group was evident.
Comparison of CYP induction in wild-type and Ppara-null mice. After gemfibrozil feeding for 7 days, mRNAs encoded by the PPARa target genes Cyp4a10, Ehhadh and Acot1 were highly induced in wild-type mice but not in Ppara-null mice ( fig. 4A ), which indicated that PPARa was differentially activated in the two mouse lines as expected. Expression of Cyp3a11 mRNA in gemfibrozil-fed mice was 4.3 times higher compared with the control group in wild-type mice ( fig. 4B ), while in Ppara-null mice, the Cyp3a11 mRNA level was 13 times higher than in the control group. Cyp2b10 mRNA was induced by 3.2 times in wild-type mice and 17 times in Ppara-null mice, respectively. Induction of Cyp2c37 (2.5 times) was observed only in Ppara-null mice and not in wildtype mice (fig. 3A) . The mRNA results indicated that activated PPARa played a suppressive role in CYP induction by gemfibrozil, which was evident for Cyp3a11 and Cyp2b10, moderate for Cyp2c37 and negative for Cyp2c39.
Induction of Cyp3a, Cyp2b and Cyp2c mRNAs in wild-type mice was not as significant as the above 14-day treatment, probably due to the shorter treatment (7 days). But the levels of Cyp3a, Cyp2b and Cyp2c mRNAs were significantly higher in Ppara-null mice than in wild-type mice ( fig. 5A ). For CYP3A, the protein level observed was 1.4 times in wild-type mice, a little lower than the two times increase in Ppara-null mice. Notably, the protein level of CYP2B was higher in Ppara-null compared with wild-type mice after gemfibrozil treatment. CYP2C protein levels were robustly induced in Ppara-null mice treated with gemfibrozil, which is in accordance with above mRNA results ( fig. 5B) .
By in vitro activity analysis, the activity of CYP3A, CYP2C and CYP2B was increased in both wild-type or Ppara-null mice compared with their control groups ( fig. 6 ). The activity of CYP3A was increased 1.8 times in wild-type mice and 3.5 times in Ppara-null mice. For the 6b-OH-T, the increase was only found in Ppara-null mice (1.6 times). The activity increase in CYP2B and CYP2C was only observed in Pparanull mice by 1.8 and 1.6 times, respectively.
Discussion
Classically, PPARa is involved in modulating lipid homoeostasis and also has a role in hepatic metabolism of glucose, amino acid and bile acid [20] . PPARa's role in the induction of CYPs and UGTs was reported but not completely understood at the molecular level other than the known Cyp4a as PPARa target gene [16, 17] . PFDA, an activator of PPARa, induced Cyp2b10 (20 times), Cyp3a11 (two times) and Cyp4a14 (32 times) in wild-type but not in Ppara-null mice [16] . The above data indicated a role for PPARa in CYP induction by exogenous agonists. For gemfibrozil, besides the well-known inhibitory drug-drug interaction, its inductive potential was recently reported [10] . In this study, the Cyp induction level of three subfamilies by gemfibrozil was much higher in Ppara-null mice than that in wild-type mice, indicating a suppressive role of PPARa.
CYP3A4 is considered to be the most important CYP subfamily for metabolism of clinical medicines [21] . Nuclear receptors PPARa, PXR, constitutive androstane receptor (CAR) are involved in the regulation of CYP3A4 expression [22, 23] . CYP3A, CYP2B and CYP4A are target genes of PXR, CAR and PPARa, respectively, with notable crosstalk among these receptors [24] . Three functional PPARa binding regions (PBR-I, PBR-II and PBR-III) within $ 12 kb of the CYP3A4 upstream sequence were ever reported [12] . So, there was a biological basis for CYP3A regulation by PPARa.
The DNA binding preference of CAR and PXR is quite similar, so it is possible that these nuclear receptors may activate both CYP3A and CYP2B genes. Using CAR-, PXR-and Ppara-null mouse models, PPARa and CAR were shown to play central roles in the induction of CYPs by PFDA. Cyp2b10 mRNA was induced to a higher extent in Ppara-null than that in wild-type mice by the PPARa activator PFDA, but not in Car-null mice [16] . These findings indicated a crosstalk between PPARa and CAR in the regulation of CYP induction by PPARa activators. The above finding also suggests that PPARa activation decreased the induction of CYP2B in wild-type mice because of its crosstalk with CAR. The data of CYP2B induction by gemfibrozil in this study were quite similar to the above report. Probably when PPARa is absent, its crosstalk with CAR would be abolished, leading to enhanced induction of the Cyp2b10 gene.
Similarly for the CYP2C subfamilies, they were induced much more in Ppara-null mice than what was seen in wildtype mice. An early study reported that peroxisome proliferators down-regulated liver-specific genes including CYP2C family members, which were dependent on PPARa [25] . In human primary hepatocytes, PPARa binds a peroxisome proliferator response element (DR1-B) in the promoter of CYP2C8 gene, suggesting the basis for direct action of PPARa on the CYP2C gene expression [9] . Another group found that direct binding of PPARa to a DR-1 motif located at positions -2762/-2775 bp upstream of the Cyp2C8 was involved in regulation of human CYP2C8 by PPARa [26] . PPARa activators induce the pantothenate kinase 1 gene and miR107, and the latter down-regulated CYP2C8 protein level in human liver [27] . Additionally, Cyp2b and Cyp2c subfamilies are target genes of the transcription factor signal transducer and activator of transcription 5B, which was regulated by growth hormone signalling and crosstalk among nuclear factors [28] . So, diverse mechanisms might be involved in the regulation of the CYP2C subfamily by PPARa agonists.
Gemfibrozil's molecular weight is only 250.35 and its absorption is about 1.5 hr, suggesting its diffusion and distribution in hepatic tissues are quite easy. After a 14-day treatment, trough concentration of gemfibrozil did not differ between wild-type and Ppara-null mice [13] . CYP-mediated depletion and UGT-mediated depletion of gemfibrozil were 303 and 1607 nmol/min./mg in rat liver microsome versus 86 and 243 nmol/min./mg in human liver microsome, suggesting that phase I metabolism contributed quite less to elimination of gemfibrozil [29] . These data indicated the chance was slim that self-induction of CYP by gemfibrozil or other pharmacokinetic variations might interfere with the pharmacodynamic actions.
There are three marker responses to evaluate CYP induction potential of compounds, namely mRNA level, protein level and activity level. The CYP activity was considered as gold standard to confirm the induction potential of given compounds. In this study, three marker responses and dose relationship were used to confirm the induction potential of gemfibrozil. The dose-response experiment in wild-type mice and suppression experiment in Ppara-null mice were performed separately. The weaker regulation of CYPs in the second experiment could be explained by shorter treatment time. Although the CYP2C mRNA was not strictly consistent with its protein and activity levels in Ppara-null mice, the CYP induction tendency was affirmative and the suppressive effect was clear. Thus, the conclusion could be made by combination of the three responses mentioned above for three Cyp subfamilies.
Conclusively in this study, gemfibrozil induced CYP3A, CYP2B and CYP2C in a dose-dependent manner in wildtype mice, while induction of these CYPs was stronger in the Ppara-null mice. These data indicated that the induction potential of CYPs by gemfibrozil was inhibited by PPARa, suggesting a potential role of this receptor in drug-drug interactions as well as metabolic diseases treated with fibrates.
